Search the Newsreel

Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

Biogen has increased its full-year revenue guidance, now expecting a mid-single-digit percentage increase, a significant turnaround from its previous outlook of a similar decline. This positive revision comes as the company's new growth portfolio of drugs successfully offsets falling revenues from its established multiple …

Biogen Number of Employees 2026 | Employee Count & Headcount Data

Biogen, Inc. (BIIB) reported approximately 7,578 total employees worldwide as of March 2026, marking a 13.6% decline from 2023. Despite this, the company is actively hiring, with 572 active job postings in 2026, a 37.6% increase from the previous year. The workforce is concentrated …

Biogen Inc (BIIB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Biogen Inc (BIIB), indicating its current valuation score of 8.73, ranking it 73rd out of 155 in the Pharmaceuticals industry. It highlights the company's P/E ratio of 21.99, which is significantly below its recent high but above …

Biogen (BIIB) Earnings Date and Reports 2026 $BIIB

Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings

Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here's what to look for. Biogen beat analysts' revenue expectations last quarter, reporting revenues of $2.48 billion, up 1.9% …

Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating

Barclays has increased its price target for Biogen Inc. (BIIB) to $200, up from the previous $185, while retaining an "Equalweight" rating on the stock. This adjustment reflects a revised analyst outlook on the pharmaceutical company. The article also lists recent analyst actions from …

Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS

Wall Street anticipates a significant earnings decline for Biogen Inc. in its second-quarter 2026 results, with analysts expecting $2.10 EPS on July 29th. This forecast represents a 61.6% year-over-year EPS drop and a 7.2% revenue contraction, reflecting substantial uncertainty and a sharp deterioration in …

Biogen Inc. stock underperforms Monday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 1.01% on Monday, closing at $200.14, despite a positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, highlighting Biogen's underperformance compared to its competitors. This decline …

(BIIB) Volatility Zones as Tactical Triggers

This article analyzes Biogen Inc. (NASDAQ: BIIB), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors. The report details specific entry, target, …

Orbimed Advisors LLC Makes New $11.29 Million Investment in Biogen Inc. $BIIB

Orbimed Advisors LLC has acquired a new stake in Biogen Inc. (NASDAQ:BIIB) during the first quarter, investing approximately $11.29 million for 61,600 shares. This investment comes as several other hedge funds also adjusted their positions in the biotechnology company. Biogen recently reported strong quarterly …

Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Moderate Buy" by Analysts

Biogen Inc. (NASDAQ:BIIB) has received a consensus "Moderate Buy" rating from 32 analysts, with an average 12-month price target of $220.57. This target is higher than its current share price of $202.19, reflecting positive sentiment from several firms. The company also reported strong quarterly …

Biogen stock trades steady as Alzheimer’s franchise and pipeline shape earnings outlook

Biogen (BIIB) stock is navigating a transition as it balances slowing revenue from older multiple sclerosis products with the growth potential of its Alzheimer's drug Leqembi and a refocused neurology pipeline. The company reported $9.83 billion in revenue and $1.7 billion in net income …

Dimensional Fund Advisors LP Increases Stock Position in Biogen Inc. $BIIB

Dimensional Fund Advisors LP significantly increased its stake in Biogen Inc. by 12.3% during the first quarter, adding 118,474 shares to reach a total of 1,079,119 shares valued at $197.9 million. This increase is part of a broader trend of institutional investors growing their …

Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?

Biogen is expected to surpass analyst expectations for its Q2 2026 earnings, despite anticipated declines in sales of its established MS drugs like Tecfidera and Tysabri due to generic and biosimilar competition. The company's sales are projected to be bolstered by new product growth …

First Trust Advisors LP Purchases 108,111 Shares of Biogen Inc. $BIIB

First Trust Advisors LP increased its stake in Biogen Inc. by 19.1% in the first quarter, acquiring an additional 108,111 shares to hold 673,958 shares valued at $123.6 million. This comes as Biogen reported strong quarterly results, beating analyst expectations for EPS and revenue. …

At-Home LEQEMBI Autoinjector And New Tau Data Might Change The Case For Investing In Biogen (BIIB)

Biogen recently received US FDA approval for its at-home LEQEMBI IQLIK autoinjector for early Alzheimer's treatment and reported positive Phase 2 CELIA data for diranersen, showing tau reduction. These developments suggest Biogen is a key player in Alzheimer's treatment, expanding options for both amyloid …

Biogen CEO: Lessons from Biopharma on Leading Reinvention

Biogen CEO Chris Viehbacher discusses his framework for leading reinvention in the biopharma industry, emphasizing the structural necessity of transformation due to patent expirations. He highlights the importance of assessing pipeline, capabilities, and people to build a credible vision for the future, rather than …

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

Biogen Inc. stock underperforms Wednesday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 2.67% on Wednesday to $197.74, underperforming the broader stock market, which also saw declines for the S&P 500 Index and Dow Jones Industrial Average. The stock closed 10.00% below its 52-week high reached on June 29th.

Former Biogen Executive to Lead Research at Formation Bio

Formation Bio has appointed former Biogen Inc. research head Michael Ehlers as its new chief scientific officer. Ehlers, a veteran in drug and biotech research, joins the AI-focused health startup which has raised over $615 million from various private and venture investors, including Sam …

Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1

The article provides financial information for Biogen Inc. (BCS:BIIB1) on the Santiago Stock Exchange, specifically focusing on its total liabilities and shareholders' equities. It appears to be a financial data page from TradingView, offering an overview of the company's financial metrics. The page is …

Discontinued operations of Biogen Inc. – BCS:BIIB0

This article from TradingView indicates that Biogen Inc.'s operations, specifically under the ticker BCS:BIIB0 on the Santiago Stock Exchange, have been discontinued. The page displays "No trades" and is focused on financial data and stock information for the company.

BofA cuts Biogen stock price target on higher expectations bar

BofA Securities has lowered its price target for Biogen Inc. (NASDAQ:BIIB) to $215 from $217, maintaining a Neutral rating, citing a higher bar for sustaining momentum after recent strong performance. Despite the cut, the stock has seen a 63% return over the past year …

BofA Securities Adjusts Biogen Price Target to $215 From $217

BofA Securities has lowered its price target for Biogen (NASDAQ: BIIB) shares to $215 from $217. This adjustment follows other recent analyst updates, including Guggenheim maintaining a Buy rating with a $280 target and Goldman Sachs maintaining a Buy rating with a $271 target. …

Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There?

Biogen (BIIB) is gaining attention due to recent Alzheimer's updates, including FDA approval for LEQEMBI injections and new Phase 2 data for diranersen. Despite recent positive share price momentum, the stock is considered 9% undervalued with a fair value estimated at $219 per share, …

Biogen’s 11.3M-share rebound restores pressure, but the signal stops short of a fresh buy

BIIB rose 3.4% in the latest week on nearly double its 13-week volume, keeping a 45-week Trend Signal intact while Healthcare breadth remains selective.

Biogen Brings On Spur Therapeutics CEO As Legal Chief

Biogen Inc. has appointed the CEO of an overseas gene therapy company as its new legal chief, effective next month. The article highlights the new legal chief's combined legal expertise and broad experience. The full article content is behind a paywall, offering only a …

Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.86% Potential Upside Amid Robust Therapeutic Portfolio

Biogen Inc. (BIIB) presents a compelling investment opportunity in the healthcare sector, backed by a robust therapeutic portfolio in neurological conditions. With a market capitalization of $30.41 billion and a current trading price of $205.99, analysts project a potential upside of 9.86%, targeting $226.29. …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Biogen Inc. (BIIB) purchasers. This investigation follows a 6.4% stock price drop after Biogen announced that its Phase 2 CELIA study for diranersen failed to meet its primary endpoints on May 14, …

Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer

Biogen Inc. has appointed Michael J. Parini as its new chief legal officer, effective August 3rd, where he will oversee the company's global legal and compliance functions and report to the CEO. Parini brings over two decades of experience in the biopharmaceutical industry, having …

Is Biogen (BIIB) a Buy, Hold, or Sell Right Now

Biogen (BIIB) faces a complex market, balancing declining legacy revenue with promising new Alzheimer's and rare disease therapies. Despite a mixed analyst sentiment, recent upgrades and a significant potential upside to the consensus price target suggest cautious optimism. Investors should evaluate Biogen's strong valuation …

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

Biogen's shares fell by 8.2% after presenting data from its phase II CELIA study for the experimental Alzheimer’s drug, diranersen, which failed to meet its primary endpoint. Although the drug showed meaningful reductions in cognitive decline, it did not demonstrate the expected dose-response relationship, …

Biogen names Michael Parini as chief legal officer

Biogen Inc. has appointed Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of experience in the biopharmaceutical industry, having previously served as CEO of Spur Therapeutics and held leadership roles at Vertex Pharmaceuticals and …

Form S-1 Biogen Inc For: 15 July By Investing.com

This article from Investing.com announces the filing of Form S-1 by Biogen Inc. on July 15. The content primarily consists of navigation links, market data, and unrelated news headlines, providing minimal specific details about the Biogen filing itself.

Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s Data - Has The Bull Case Changed?

Biogen's stock is down 6.7% following the launch of at-home LEQEMBI IQLIK for early Alzheimer's and new positive Phase 2 data for diranersen. The at-home option for LEQEMBI aims to improve access and uptake, which is crucial for Biogen's investment narrative amidst revenue pressure …